Research
Hormonal
The dual agonist tirzepatide has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.
Practitioners may consider tirzepatide as a more effective option for weight loss in obese patients.
StrongSupportsmedium confidence
The dual agonist tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist.
Why this rating
Based on the review of pharmacotherapy strategies.
Source
Why does <scp>GLP</scp> ‐1 agonist combined with <scp>GIP</scp> and/or <scp>GCG</scp> agonist have greater weight loss effect than <scp>GLP</scp> ‐1 agonist alone in obese adults without type 2 diabetes?
Yuchen Jiang et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.16106
reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →